Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06749795
PHASE1
LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
Sponsor: Liveome Inc.
View on ClinicalTrials.gov
Summary
A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis
Official title: A Randomized, Double-Blind, Placebo Controlled, Multi -Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-03-24
Completion Date
2026-03-24
Last Updated
2025-03-24
Healthy Volunteers
No
Conditions
Interventions
DRUG
LIV001
Orally administered for 8 weeks
DRUG
Placebo
Orally administered for 8 weeks
Locations (1)
Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
Wroclaw, Poland